NCT04640142 - Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 4, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions

Primary Immune Deficiency

Interventions

BIOLOGICAL

Newnorm

Newnorm is a 20% human normal immunoglobulin for SC infusion.

Trial Locations (24)

133

Octapharma Research Site, Roma

1097

Octapharma Research Site, Budapest

4032

Octapharma Research Site, Debrecen

21162

Octapharma Research Site, White Marsh

31100

Octapharma Research Site, Treviso

33021

Octapharma Research Site, Hollywood

33701

Octapharma Research Site, St. Petersburg

34986

Octapharma Research Site, Port Saint Lucie

40217

Octapharma Research Site, Louisville

60612

Octapharma Research Site, Chicago

64111

Octapharma Research Site, Kansas City

66211

Octapharma Research Site, Overland Park

68046

Octapharma Research Site, Omaha

79010

Octapharma Research Site, Lviv

79035

Octapharma Research Site, Lviv

80112

Octapharma Research Site, Centennial

80131

Octapharma Research Site, Napoli

80337

Octapharma Research Site, Munich

92697

Octapharma Research Site, Irvine

04129

Octapharma Research Site, Leipzig

00161

Octapharma Research Site, Roma

30-663

Octapharma Research Site, Krakow

833 40

Octapharma Research Site, Bratislava

04209

Octapharma Research Site, Kyiv